Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT07624526
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 95 Years
Healthy Volunteers
Not accepted

Interventions

  • Suzetrigine — DRUG
    Suzetrigine is an orally administered, selective NaV1.8 voltage-gated sodium channel inhibitor being investigated as a non-opioid analgesic for the treatment of pain through inhibition of pain signal transmission in peripheral sensory neurons.

Study Details

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Key Dates

Start date
Jul 31, 2026
Status verified
May 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Suzetrigine Regimen Arm
    Suzetrigine (JOURNAVX®) administered orally consisting of a course that lasts up to a maximum of 14 days. The starting dose will be 100 mg orally taken as two 50 mg tablets on an empty stomach (at least 1 hour before or 2 hours after food). Maintenance dosing will begin 12 hours after the initial dose, at which point patients will take 50 mg orally every 12 hours.

Primary Outcome Measure

Mean pain intensity score on the Numeric Rating Scale (NRS) [ Time Frame: Day 0-14 postoperative ]

Central Contacts

Locations (3)

FacilityCityStateZIP
Emory ClinicAtlantaGeorgia30322
Emory Clinic at Executive ParkAtlantaGeorgia30329
Emory Orthopaedics and Spine CenterAtlantaGeorgia30329

Find similar trials in Atlanta, GA

By condition
Osteoarthritis (other)
By specialty
OrthopedicsMusculoskeletal disorders
By research site
Emory Clinic· Atlanta, GAEmory Clinic at Executive Park· Atlanta, GAEmory Orthopaedics and Spine Center· Atlanta, GA

Related Studies